Oral decitabine-cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study |
Jan 2024 |
Lancet Hematology |
Myelodysplastic Syndromes (MDS) |
Sabatolimab plus hypomethylating agents in previously untreated patients with higher-risk myelodysplastic syndromes (STIMULUS-MDS1): a randomised, double-blind, placebo-controlled, phase 2 trial |
Jan 2024 |
Lancet Hematology |
Myelodysplastic Syndromes (MDS) |
Haploidentical Transplant with Post-Transplant Cyclophosphamide for Acute Myeloid Leukaemia and Myelodysplastic Syndromes Patients: The Role of Previous Lines of Therapy |
Jan 2024 |
Mediterranean Journal of Hematology and Infectious Diseases |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) |
Paroxysmal Nocturnal Hemoglobinuria |
Jan 2024 |
StatPearls |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
Morphologic Characteristics of Myelodysplastic Syndromes |
Dec 2023 |
Clinics in Laboratory Medicine |
Myelodysplastic Syndromes (MDS) |
Deciphering treatment patterns in non-severe/moderate aplastic anemia: an international observational study |
Dec 2023 |
Leukemia |
Aplastic Anemia |
Acute Myeloid Leukemia Arising from Myelodysplastic Syndromes |
Dec 2023 |
Clinics in Laboratory Medicine |
Myelodysplastic Syndromes (MDS) |
Treatment Considerations of Myelodysplastic Syndromes/Neoplasms for Pathologists |
Dec 2023 |
Clinics in Laboratory Medicine |
Myelodysplastic Syndromes (MDS) |
Transfusion Support of Patients with Myelodysplastic Syndromes |
Dec 2023 |
Clinics in Laboratory Medicine |
Myelodysplastic Syndromes (MDS) |
Diagnosis and Classification of Myelodysplastic Syndromes with Mutated TP53 |
Dec 2023 |
Clinics in Laboratory Medicine |
Myelodysplastic Syndromes (MDS) |